Literature DB >> 23258653

Risk factors for blindness in patients with open-angle glaucoma followed-up for at least 15 years.

Jayter Silva Paula1, João Marcello Furtado, Arles Silva Santos, Roberto de Mattos Coelho, Eduardo Melani Rocha, Maria de Lourdes Veronese Rodrigues.   

Abstract

PURPOSE: To determine the proportion of blindness and investigate the relationships between risk factors based on clinical characteristics and development of blindness in patients with primary open-angle glaucoma (POAG) treated for at least 15 years.
METHODS: A retrospective observational chart review was performed with 403 patients referred to a tertiary level hospital, each with a diagnosis of primary open-angle glaucoma, treated for at least 15 years. Blindness attributable to glaucoma was defined based on visual acuity and/or visual field tests. Variables considered to be possible risk factors for blindness were evaluated using odds ratio (OR), confidence interval (95% CI), and univariate and multivariate analyses.
RESULTS: Thirty-one patients became blind [13/53 (24.5%) - unilaterally and 18/53 (34%) - bilaterally] during the follow-up period of treatment (19.5 ± 4.6 years, range 15-31 years). Multivariate statistics with regression analysis revealed that persistency on initial therapy ≤6 months was significantly associated with blindness, both unilateral (OR: 8.4; 95% CI: 1.3-56.4) and bilateral (OR: 7.2; 95% CI: 1.3-39.6). Other potential factors such as race, age, gender or number of medications were not associated with blindness.
CONCLUSION: Blindness from primary open-angle glaucoma was not uncommon in this population of treated patients after the long follow-up period proposed. Persistence rates with the first therapy, as measured by a medical decision to change, were low. Persistence ≤6 months was statistically associated with the development of unilateral and bilateral blindness from glaucoma.

Entities:  

Mesh:

Year:  2012        PMID: 23258653     DOI: 10.1590/s0004-27492012000400004

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  9 in total

1.  Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up.

Authors:  Paula Anne Newman-Casey; Taylor Blachley; Paul P Lee; Michele Heisler; Karen B Farris; Joshua D Stein
Journal:  Ophthalmology       Date:  2015-08-25       Impact factor: 12.079

2.  A novel EyePhone© App for improving adherence to glaucoma therapy.

Authors:  Ari Leshno; Dan Gaton; Reut Singer; Elior Eliasi; Ofri Vorobichik-Berar; Shiran Madgar; Ori Stern; Wasim Jaber; Noa Kapelushnik; Alon Skaat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-02-02       Impact factor: 3.117

3.  The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey.

Authors:  Paula Anne Newman-Casey; Alan L Robin; Taylor Blachley; Karen Farris; Michele Heisler; Ken Resnicow; Paul P Lee
Journal:  Ophthalmology       Date:  2015-04-24       Impact factor: 12.079

4.  Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota.

Authors:  Mehrdad Malihi; Edney R Moura Filho; David O Hodge; Arthur J Sit
Journal:  Ophthalmology       Date:  2013-10-25       Impact factor: 12.079

5.  Glaucoma Blindness at a Tertiary Eye Care Center.

Authors:  Jordan S Stone; Kelly W Muir; Sandra S Stinnett; Jullia A Rosdahl
Journal:  N C Med J       Date:  2015 Sep-Oct

6.  One-Year Outcomes of Second-Generation Trabecular Micro-Bypass Stents (iStent Inject) Implantation with Cataract Surgery in Different Glaucoma Subtypes and Severities.

Authors:  Ali Salimi; Julie Lapointe; Paul Harasymowycz
Journal:  Ophthalmol Ther       Date:  2019-09-19

7.  Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data.

Authors:  Yunjeong Jang; Donghyun Jee; Donghwan Lee; Nam-Kyong Choi; SeungJin Bae
Journal:  Int J Environ Res Public Health       Date:  2021-04-13       Impact factor: 3.390

8.  Topical Medication Adherence and Visual Field Progression in Open-angle Glaucoma: Analysis of a Large US Health Care System.

Authors:  Yu-Hsiang Shu; Jun Wu; Tiffany Luong; Cynthia Mattox; Ervin N Fang; Brian L Lee; Jason P Jones; Joanna Campbell; Vanessa Shih; Changgeng Zhao; Donald S Fong
Journal:  J Glaucoma       Date:  2021-12-01       Impact factor: 2.503

9.  Progression to severe visual impairment and blindness in POAG patients: pace and risk factors-a cohort study using German health claims data.

Authors:  Sophia Nestler; Daniel Kreft; Gabriele Doblhammer; Rudolf F Guthoff; Stefanie Frech
Journal:  BMJ Open Ophthalmol       Date:  2022-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.